Please login to the form below

Not currently logged in
Email:
Password:

Sigma-Tau Pharmaceuticals appoints CEO

Interim CEO Michael Minarich takes up the post in a permanent capacity

Sigma-Tau Pharmaceuticals Michael MinarichRare disease specialist Sigma-Tau Pharmaceuticals has appointed Michael Minarich as chief executive officer.

Micharich has served as the company's interim chief executive since July last year, bringing over 30 years of marketing and business development experience in the pharmaceutical industry to the role.

Prior to joining Sigma-Tau, Micharich was the Pharmacia Corporation's market company president in the Czech Republic and oversaw the merger of Searle with Pharmacia and Upjohn.

He has considerable experience in growing startup businesses and integrating over-the-counter and consumer product mergers and acquisitions, having spent 20 years doing so across Asia, Canada and Europe.

Marco Brughera, chief executive and global head of rare disease at Sigma-Tau Rare Disease, said: “Mr Minarich has demonstrated outstanding leadership over the past year, and his appointment comes at a time of development in the company, as it expands through registration, life-cycle management and commercialisation of its proprietary research and development pipeline.

“The appointment of the chief executive role reflects the commitment Sigma-Tau has to the field of rare diseases, and to the significant impact we expect these medicines will ultimately have on their respective physician and patient communities.”

9th August 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics